Amicus Therapeutics' (FOLD) "Hold" Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Amicus Therapeutics (NASDAQ:FOLD - Free Report) in a research report report published on Thursday morning,Benzinga reports.

A number of other analysts also recently issued reports on FOLD. Morgan Stanley reissued an "equal weight" rating and set a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Cantor Fitzgerald reissued an "overweight" rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. JPMorgan Chase & Co. lifted their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, November 12th. StockNews.com cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday. Finally, Guggenheim raised their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $16.75.

Amicus Therapeutics Trading Up 1.7 %

NASDAQ:FOLD traded up $0.16 on Thursday, hitting $9.35. 3,182,352 shares of the stock were exchanged, compared to its average volume of 2,307,549. The stock has a fifty day moving average of $9.56 and a 200-day moving average of $10.42. The stock has a market cap of $2.87 billion, a PE ratio of -51.92, a PEG ratio of 1.51 and a beta of 0.61. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. Amicus Therapeutics has a fifty-two week low of $8.78 and a fifty-two week high of $14.02.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,884,273.08. The trade was a 0.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Amicus Therapeutics

Hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP boosted its stake in Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company's stock valued at $255,936,000 after acquiring an additional 2,856,101 shares during the last quarter. Tempus Wealth Planning LLC acquired a new stake in shares of Amicus Therapeutics in the 4th quarter valued at about $259,000. Neo Ivy Capital Management bought a new position in shares of Amicus Therapeutics during the third quarter worth about $702,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Amicus Therapeutics by 51.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 222,934 shares of the biopharmaceutical company's stock worth $2,381,000 after purchasing an additional 75,807 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Amicus Therapeutics by 10.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company's stock worth $28,486,000 after purchasing an additional 242,672 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.